SUBSCRIBE
SUBSCRIBE
News   Drug Development

Biocryst Pharmaceuticals Initiates a Phase 2b Study of BCX4208 as Add-on Therapy in Gout Patients Not Responding to Allopurinol Alone

December 22, 2010 | 
1 min read
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the initiation of a Phase 2b study of BCX4208 as add-on therapy in gout patients who have not responded to allopurinol therapy alone.
Clinical research Phase II
BioCryst Pharmaceuticals, Inc.
MORE ON THIS TOPIC
Business vision and target. Businessman holding telescope standing on arrow up go to success in career. Concept business, Achievement, Character, Leader, Vector illustration flat
Drug Development
5 Second-Half Biopharma Milestones To Watch
July 7, 2025
 · 
8 min read
 · 
Tristan Manalac
businessman Climbing mountain. Symbol of success, career, leadership and goal
Immuno-oncology
Four Therapies Hanging On in Troubled TIGIT Space
July 7, 2025
 · 
9 min read
 · 
Tristan Manalac
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
July 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Painful female periods concept. Vector flat character illustration. Woman standing and suffering menstrual abdominal pain isolated on pink background. Design for health care.
Women’s Health
Organon’s Endometriosis Drug Discontinued After Failing To Improve Pain
July 2, 2025
 · 
1 min read
 · 
Annalee Armstrong